Skip to main content
Fig. 1 | Journal of Nanobiotechnology

Fig. 1

From: Specific drug delivery efficiently induced human breast tumor regression using a lipoplex by non-covalent association with anti-tumor antibodies

Fig. 1

The characteristics of the drug/LPPC/targeting antibody complex. a The scheme for curcumin/LPPC/Herceptin preparation. PEI provides its positive charges of amine groups interact with the carboxy groups of antibodies. b The maximal-binding capacity of Herceptin to LPPC. LPPC (40 μg) was incubated with different amounts of Herceptin, and the maximal amount of bound protein was analyzed with the Bradford Assay. c The particle size and d zeta-potential of the drug/LPPC/targeting antibodies complex. e The effect of Herceptin association on curcumin release from the curcumin/LPPC complexes. Curcumin/LPPC or Curcumin/LPPC/Herceptin complexes were incubated in PBS at 4, 25 or 37 °C. As previous described in the materials and methods section, the concentration of curcumin in each supernatant was measured at various incubation time points and compared with the total curcumin concentration. All values represent the mean ± SD, ***p < 0.001 (n = 3)

Back to article page

Journal of Nanobiotechnology

ISSN: 1477-3155

Contact us